Can-Fite BioPharma Ltd. filings document foreign-private-issuer disclosures for a clinical-stage biotechnology company whose American Depositary Shares trade under CANF. Its Form 6-K reports furnish press releases, annual and special meeting materials, proxy statements, voting instruction cards for ADS holders, and shareholder-vote results.
The company’s regulatory record covers clinical and regulatory updates for A3AR drug candidates, Namodenoson and Piclidenoson patent matters, partner-related development disclosures, operating and financial results, capital-structure items, registration-statement incorporation for Form S-8 and Form F-3 filings, governance matters, and risks connected to drug development and public-company financing.
Can-Fite BioPharma announced the adjournment of its Annual General Meeting of Shareholders originally scheduled for June 23, 2025, due to lack of quorum. The meeting has been rescheduled for June 30, 2025, at 3:00 p.m. Israel time and will be held at the company's offices in Ramat Gan, Israel.
The Form 6-K was signed by Motti Farbstein, who serves as both Chief Executive Officer and Chief Financial Officer of the company. This regulatory filing fulfills the company's obligation to report material events to shareholders under Securities Exchange Act requirements.